Literature DB >> 26296711

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

Sandesh C S Nagamani1, George A Diaz2, William Rhead3, Susan A Berry4, Cynthia Le Mons5, Uta Lichter-Konecki6, James Bartley7, Annette Feigenbaum8, Andreas Schulze9, Nicola Longo10, William Berquist11, Renata Gallagher12, Dennis Bartholomew13, Cary O Harding14, Mark S Korson15, Shawn E McCandless16, Wendy Smith17, Jerry Vockley18, David Kronn19, Robert Zori20, Stephen Cederbaum21, J Lawrence Merritt22, Derek Wong21, Dion F Coakley23, Bruce F Scharschmidt23, Klara Dickinson24, Miguel Marino14, Brendan H Lee25, Masoud Mokhtarani23.   

Abstract

BACKGROUND: Health care outcomes have been increasingly assessed through health-related quality of life (HRQoL) measures. While the introduction of nitrogen-scavenging medications has improved survival in patients with urea cycle disorders (UCDs), they are often associated with side effects that may affect patient compliance and outcomes.
METHODS: Symptoms commonly associated with nitrogen-scavenging medications were evaluated in 100 adult and pediatric participants using a non-validated UCD-specific questionnaire. Patients or their caregivers responded to a pre-defined list of symptoms known to be associated with the use of these medications. Responses were collected at baseline (while patients were receiving sodium phenylbutyrate [NaPBA]) and during treatment with glycerol phenylbutyrate (GPB).
RESULTS: After 3 months of GPB dosing, there were significant reductions in the proportion of patients with treatment-associated symptoms (69% vs. 46%; p<0.0001), the number of symptoms per patient (2.5 vs. 1.1; p<0.0001), and frequency of the more commonly reported individual symptoms such as body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn (p<0.05). The reduction in symptoms was observed in both pediatric and adult patients. The presence or absence of symptoms or change in severity did not correlate with plasma ammonia levels or NaPBA dose.
CONCLUSIONS: The reduction in symptoms following 3 months of open-label GPB dosing was similar in pediatric and adult patients and may be related to chemical structure and intrinsic characteristics of the product rather than its effect on ammonia control.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ammonia; Glycerol phenylbutyrate; Health-related quality of life; Patient-reported outcomes; Sodium phenylbutyrate; Treatment-related symptoms

Mesh:

Substances:

Year:  2015        PMID: 26296711      PMCID: PMC4804346          DOI: 10.1016/j.ymgme.2015.08.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

Authors:  Martin R Stockler; Felix Hilpert; Michael Friedlander; Madeleine T King; Lari Wenzel; Chee Khoon Lee; Florence Joly; Nikolaus de Gregorio; José Angel Arranz; Mansoor Raza Mirza; Roberto Sorio; Ulrich Freudensprung; Vesna Sneller; Gill Hales; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

2.  Note on the sampling error of the difference between correlated proportions or percentages.

Authors:  Q McNEMAR
Journal:  Psychometrika       Date:  1947-06       Impact factor: 2.500

3.  Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Authors:  Uta Lichter-Konecki; G A Diaz; J L Merritt; A Feigenbaum; C Jomphe; J F Marier; M Beliveau; J Mauney; K Dickinson; A Martinez; M Mokhtarani; B Scharschmidt; W Rhead
Journal:  Mol Genet Metab       Date:  2011-05-05       Impact factor: 4.797

4.  Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.

Authors:  Brendan Lee; William Rhead; George A Diaz; Bruce F Scharschmidt; Asad Mian; Oleg Shchelochkov; J F Marier; Martin Beliveau; Joseph Mauney; Klara Dickinson; Antonia Martinez; Sharron Gargosky; Masoud Mokhtarani; Susan A Berry
Journal:  Mol Genet Metab       Date:  2010-03-23       Impact factor: 4.797

5.  Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Authors:  Wendy Smith; George A Diaz; Uta Lichter-Konecki; Susan A Berry; Cary O Harding; Shawn E McCandless; Cindy LeMons; Joe Mauney; Klara Dickinson; Dion F Coakley; Tristen Moors; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee
Journal:  J Pediatr       Date:  2013-01-13       Impact factor: 4.406

6.  Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.

Authors:  George A Diaz; Lauren S Krivitzky; Masoud Mokhtarani; William Rhead; James Bartley; Annette Feigenbaum; Nicola Longo; William Berquist; Susan A Berry; Renata Gallagher; Uta Lichter-Konecki; Dennis Bartholomew; Cary O Harding; Stephen Cederbaum; Shawn E McCandless; Wendy Smith; Gerald Vockley; Stephen A Bart; Mark S Korson; David Kronn; Roberto Zori; J Lawrence Merritt; Sandesh C S Nagamani; Joseph Mauney; Cynthia Lemons; Klara Dickinson; Tristen L Moors; Dion F Coakley; Bruce F Scharschmidt; Brendan Lee
Journal:  Hepatology       Date:  2013-01-03       Impact factor: 17.425

7.  Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion.

Authors:  M L Batshaw; S Brusilow; L Waber; W Blom; A M Brubakk; B K Burton; H M Cann; D Kerr; P Mamunes; R Matalon; D Myerberg; I A Schafer
Journal:  N Engl J Med       Date:  1982-06-10       Impact factor: 91.245

8.  Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.

Authors:  Susan A Berry; Uta Lichter-Konecki; George A Diaz; Shawn E McCandless; William Rhead; Wendy Smith; Cynthia Lemons; Sandesh C S Nagamani; Dion F Coakley; Masoud Mokhtarani; Bruce F Scharschmidt; Brendan Lee
Journal:  Mol Genet Metab       Date:  2014-02-21       Impact factor: 4.797

  8 in total
  2 in total

1.  Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.

Authors:  Aseel Bin Sawad; Arti Pothukuchy; Mark Badeaux; Victoria Hodson; Gillian Bubb; Kristina Lindsley; Jennifer Uyei; George A Diaz
Journal:  JIMD Rep       Date:  2022-03-25

2.  Switching to Glycerol Phenylbutyrate in 48 Patients with Urea Cycle Disorders: Clinical Experience in Spain.

Authors:  Elena Martín-Hernández; Pilar Quijada-Fraile; Patricia Correcher; Silvia Meavilla; Paula Sánchez-Pintos; Javier de Las Heras Montero; Javier Blasco-Alonso; Lucy Dougherty; Ana Marquez; Luis Peña-Quintana; Elvira Cañedo; María Concepción García-Jimenez; Pedro Juan Moreno Lozano; Mercedes Murray Hurtado; María Camprodon Gómez; Delia Barrio-Carreras; Mariela de Los Santos; Mireia Del Toro; María L Couce; Isidro Vitoria Miñana; Montserrat Morales Conejo; Marcello Bellusci
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.